Chronic Bronchitis News and Research

RSS

Phase 3 data of VIVACITO study evaluating effect of T+O FDC in COPD presented at ATS conference

Boehringer Ingelheim today presented results of the VIVACITO® (NCT01559116) study, the first Phase 3 data to be reported from the TOviTO® clinical trial program, evaluating the effect of the fixed-dose combination of tiotropium and olodaterol (T+O FDC) delivered via the Respimat® inhaler on lung function in people with chronic obstructive pulmonary disease (COPD).

22 May 2014

GSK reports positive results from Incruse Ellipta and Advair Diskus combination therapy in COPD patients

GlaxoSmithKline plc today presented data at the American Thoracic Society (ATS) from a late-stage clinical study.

20 May 2014

Study shows commonly used statin drug does not reduce acute COPD exacerbations

A statin drug commonly used to lower cholesterol is not effective in reducing the number and severity of flare ups from chronic obstructive pulmonary disease (COPD), according to the results of a large multicenter clinical trial designed and directed by Gerard J. Criner, MD, Director of Pulmonary and Critical Care Medicine at Temple University Hospital in Philadelphia, PA.

19 May 2014

GSK, Theravance announce availability of Anoro Ellipta in the US for COPD treatment

GlaxoSmithKline plc and Theravance, Inc. today announced that Anoro Ellipta (umeclidinium and vilanterol inhalation powder), the first once-daily product approved in the US that combines two long-acting bronchodilators in a single inhaler for the maintenance treatment of chronic obstructive pulmonary disease (COPD), is now available to retail pharmacies in the US.

28 Apr 2014

Researchers launch detailed atlas with environment and health maps

Researchers have launched a detailed atlas with environment and health maps at a fine scale across England and Wales.

25 Apr 2014

COPD sufferers can reduce risk of being hospitalized by walking 3 kilometers a day

New research in Respirology shows that suffers of Chronic obstructive pulmonary disease (COPD) can reduce their risk of being hospitalized with severe attacks, by maintaining an exercise regime of walking between three to six kilometers a day.

19 Feb 2014

Ario Pharma begins XEN-0501 Phase IIa study for treatment persistent cough in COPD patients

Ario Pharma Ltd, the Cambridge biopharmaceutical company developing innovative new approaches to treat respiratory disease, announced today that it has commenced a Phase IIa study of its TRPV1 antagonist, XEN-0501, for the treatment and prevention of cough in patients with chronic obstructive pulmonary disease (COPD). Persistent cough in COPD and other respiratory conditions present as a huge unmet medical need, with novel therapies urgently needed to improve the quality of life of patients.

11 Feb 2014

Smoking and cancer: an interview with Dr. Lewis Foxhall, VP of Health Policy, University of Texas MD Anderson Cancer Center

The report Smoking and Health: Report of the Advisory Committee to the Surgeon General, identified tobacco as the predominant cause of lung cancer in men. This was the first widely disseminated report based on scientific studies showing the clear link between smoking tobacco and serious health conditions including cancer, chronic lung diseases and heart disease.

13 Jan 2014

FDA OOPD grants orphan drug designation to Alitair's Erdosteine for treatment of bronchiectasis

Alitair Pharmaceuticals, Inc., today announced that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation for its drug candidate, Erdosteine, for the treatment of bronchiectasis. Erdosteine is a mucolytic with antibacterial, anti-inflammatory, and antioxidant properties.

7 Jan 2014

Study finds that people with COPD twice likely to develop mild cognitive impairment, memory loss

A recent Mayo Clinic study found that people with chronic obstructive pulmonary disease (COPD) are about twice as likely to develop mild cognitive impairment (MCI) -- and chances are that it will include memory loss. The study was recently published in Mayo Clinic Proceedings.

12 Dec 2013

BAL findings boost non-smoking COPD distinction

Research shows that smoking status, and not airway obstruction, determines the distribution of T cell subsets in bronchoalveolar lavage in patients with chronic obstructive pulmonary disease.

2 Dec 2013

Chronic bronchitis could indicate COPD subtype

Chronic bronchitis is common among patients with chronic obstructive disease and may represent a subtype of the disease that places patients at risk for increased severity and exacerbations, say researchers.

22 Nov 2013

Once-daily prescription medicine for COPD now available throughout the U.S.

GlaxoSmithKline plc and Theravance, Inc. today announced that BREO ELLIPTA, a once-daily prescription medicine for chronic obstructive pulmonary disease, is now available to pharmacies throughout the U.S.

30 Oct 2013

Scientists develop new drug to treat obstructive airway diseases

Scientists have developed a new drug (RPL554) that could treat obstructive airway diseases such as asthma and chronic obstructive pulmonary disease in two ways at once, according to new research published in The Lancet Respiratory Medicine.

25 Oct 2013

Leukemia drug reverses symptoms of colitis in lab tests

A drug currently on the market to treat leukemia reversed symptoms of colitis in lab tests, according to recently published findings by medical researchers with the University of Alberta.

24 Oct 2013

COPD investigational treatments: an interview with Dr. Tunde Otulana, Senior Vice President, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc.

Olodaterol is a long-acting beta2-agonist (LABA) bronchodilator delivered via the Respimat® inhaler. It is being investigated as a once daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

21 Oct 2013

Chronic bronchitis linked to poor asthma outcomes

Researchers have found that chronic bronchitis is associated with worse clinical outcomes in asthma, particularly among smokers.

26 Sep 2013

UNC receives grants from FDA and NIH to establish Tobacco Centers of Regulatory Science

The University of North Carolina at Chapel Hill received two separate grants from the U.S. Food and Drug Administration and the National Institutes of Health today as part of an on-going interagency partnership. UNC will house two of 14 Tobacco Centers of Regulatory Science, which are receiving a total of up to $53 million for tobacco-related research in fiscal year 2013.

21 Sep 2013

Inhaled corticosteroid increases risk for pneumonia reoccurrence

A University of Alberta researcher says health professionals should be cautious about prescribing inhaled corticosteroids to high-risk patients such as pneumonia survivors, citing a twofold risk for repeat infection.

19 Sep 2013

Patients with COPD show improvements in lung function with olodaterol

Data from the olodaterol Phase 3 clinical program, presented for the first time at the European Respiratory Society (ERS) Annual Congress 2013 in Barcelona, showed the addition of olodaterol 5 and 10 µg delivered once daily via the Respimat® inhaler provided improvements in lung function in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

10 Sep 2013